Curriculum Vitae

WILHELMUS (WIM) M.J. VUIST

115 John Kirk Ct.
Campbell, CA 95008
Cell (408) 796-7879
wvdf0f9a@westpost.net
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
QUALIFICATIONS PROFILE
Cancer Immunotherapy ~ Monoclonal Antibodies (mAbs) ~ Tumor Immunology
High energy and astute Senior Scientist offering seasoned knowledge and expertis
e in cancer immunotherapy coupled with a passion for preclinical research, excep
tional communication skills, and superior leadership abilities. Motivating manag
ement style with strengths in developing high achieving research groups and buil
ding consensus and support among executives. High level of patience and persiste
nce with a well rounded approach to making key recommendations. Additional exper
tise includes:
* Research Group Management
* Resource Management
* Animal Use & Care
* Preclinical Efficacy & Safety Data
* Oncology, Inflammation, and Immunity
* Preclinical Experiment Design
* Murine Tumor Model Systems
* Literature Reviews
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
EDUCATION
UNIVERSITY OF AMSTERDAM, THE NETHERLANDS CANCER INSTITUTE, DIVISION OF
IMMUNOLOGY, Amsterdam, The Netherlands
Ph.D. in Medicine, 1990
Thesis: "Monoclonal antibodies and cytokines for the treatment of malignant lymp
homa."
Advisors: Dr. C. J. M. Melief and Dr. Ph. Rumke
UNIVERSITY OF UTRECHT, Utrecht, The Netherlands
MS in Biology, 1985
Major: Tumor Immunology; Advisor: Dr. W. den Otter
Minor: Microbiology; Advisor: Dr. W. Hoekstra
Minor: Pharmacology; Advisor: Dr. D. deWied
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
POST-GRADUATE TRAINING
STANFORD MEDICAL UNIVERSITY, DEPARTMENT OF MEDICINE/ONCOLOGY, Stanford, CA
Post-doctoral Fellowship, Laboratory of Dr. Ron Levy (1993)
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
PROFESSIONAL EXPERIENCE
CEPHALON INC., Redwood City, CA (2010 - Present)
Consultant
Develop comprehensive recommendations for potential antibody targets in oncology
, inflammation and autoimmunity based on analysis of the latest medical and scie
ntific literature. Synthesize data on the biology of antigens and provide detail
ed recommendations on suitability.
Key Achievements:
* Fully clarified scientific data and constructed presentations illustrating dec
isive data for executive boards.
MEDAREX, Milpitas, CA (2006 - Present)
Consultant
Lead the design and analyze findings of preclinical experiments involving monocl
onal antibodies specific for oncology targets in appropriate murine tumor model
systems. Drive the design of preclinical toxicology experiments, including evalu
ation of findings.
Key Achievements:
* Minimized the number of animal experiments by guiding the design of syngeneic
and xenogeneic animal model experiments, resulting in significant cost savings.
Sabbatical to assume family responsibilities as the at-home parent of young chil
dren (2004 - 2006)
MEDAREX, Milpitas, CA (2001 - 2004)
Senior Scientist, Discovery Research and Cell Biology
Founded and developed the Tumor Immunology Group, which generated preclinical da
ta on seven fully human monoclonal antibodies that unequivocally led to go (5/7)
and no-go (2/7) decisions surrounding mAb development towards clinical trials.
Generated mouse monoclonal antibodies against mouse CTLA-4 in a joint effort wit
h Dr. James Allison. One antibody was utilized in syngeneic tumor models and ind
icated synergistic anti-tumor activity in combination with whole cell vaccines o
r anti-tumor mAbs.
Key Achievements:
* Charted a joint project with an Australian company to develop fully human mAbs
against an oncology target. Crafted strategy and directed a cross-functional 10
-person team in California to generate monoclonal antibodies with the desired sp
ecificity.
* Provided mentoring and training to a team of three research associates on in v
ivo and in vitro antibody animal model experiments.
CELL GENESYS, INC., Foster City, CA (1999 - 2001)
Senior Scientist, GVAX Preclinical Research Group, Preclinical Biology and Immun
ology
Steered the development of preclinical efficacy and safety data to validate use
of the genomic GM-CSF gene for the creation of GM-CSF producing whole cell vacci
nes (GVAX). Delivered insightful leadership as the GVAX preclinical research rep
resentative on the Cell Genesys Scientific Advisory Board.
Key Achievements:
* Produced crucial preclinical data that demonstrated synergistic anti-tumor act
ivity of combination treatments with GVAX and anti-CTLA-4 mAbs.
* Demonstrated a sound approach while advocating the GVAX vaccine to internal st
akeholders.
* Established relationships with a number of international scientists engaged in
the development of tumor vaccines, including Dr. D. Pardol and Dr. H. Levitsky,
Johns Hopkins University; Dr. R. Germain, National Institutes of Health (NIH);
and Dr. B. Fox, OHSU.
SANGSTAT MEDICAL CORP., Menlo Park, CA (1997 - 1999)
Senior Scientist, XenojectTM Research Project, Research and Development
Directed a research group charged with the development of a novel drug platform,
i.e. XenojectTM. Managed the Animal Facility with oversight of one animal tech
nician. Chaired the Institutional Animal Use and Care Committee (IACUC). Drafte
d Standard Operating Procedures for the animal facility.
Key Achievements:
* Uncovered an extremely low affinity among anti-?Gal antibodies in human serum
(mostly IgM) for their antigen (?GAL), preventing redirection to artificially ge
nerated ?GAL containing proteins.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
TEACHING EXPERIENCE
UNIVERSITY MAASTRICHT, DIVISIONS OF HUMAN BIOLOGY AND BIOCHEMISTRY, Maastricht,
The Netherlands (1995 - 1997)
Assistant Professor
Drove a research group exploring regulation of intracellular Ca2+ signaling in h
uman blood platelets. Played a key role in setting up a microscope system that e
nabled the study of Ca2+ signaling at the single blood platelet level.
Key Achievements:
* Produced six publications which appeared in peer reviewed journals.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
ADDITIONAL EXPERIENCE
ACADEMIC HOSPITAL LEIDEN, DIVISION OF IMMUNOHEMATOLOGY/BLOODBANK, Leiden, The Ne
therlands (1993 - 1995)
Research Fellow
Examined the mechanism of IvIg in inhibiting cell growth.
DUTCH CANCER INSTITUTE, DIVISION OF IMMUNOLOGY, Amsterdam, The Netherlands (Year
- Year)
Ph.D. Student
Clarified the mechanism(s) of anti-cancer activity of mouse monoclonal antibodie
s in a xenograft model of human B cell lymphoma. Presented data that resulted in
an industry standard paper on antibody dependent cellular cytotoxicity (ADCC).
(Vuist, et.al, Cancer Immunol. Immunoth., 93, 163-170, 1993)
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
PUBLICATIONS
1. van Gorp, R.M., M.A. Feijge, W.M. Vuist, M.B. Rook, and J.W. Heemskerk. 2002.
Irregular spiking in free calcium concentration in single, human platelets. Reg
ulation by modulation of the inositol trisphosphate receptors. Eur J Biochem 269
:1543-1552.
2. Chiang, T.R., L. Fanget, R. Gregory, Y. Tang, D.L. Ardiet, L. Gao, C. Meschte
r, A.P. Kozikowski, R. Buelow, and W.M. Vuist. 2000. Anti-Gal antibodies in huma
ns and 1, 3alpha-galactosyltransferase knock-out mice. Transplantation 69:2593-2
600.
3. Keularts, I.M., R.M. van Gorp, M.A. Feijge, W.M. Vuist, and J.W. Heemskerk. 2
000. alpha(2A)-adrenergic receptor stimulation potentiates calcium release in pl
atelets by modulating cAMP levels. J Biol Chem 275:1763-1772.
4. Heemskerk, J.W., P. Siljander, W.M. Vuist, G. Breikers, C.P. Reutelingsperger
, M.J. Barnes, C.G. Knight, R. Lassila, and R.W. Farndale. 1999. Function of gly
coprotein VI and integrin alpha2beta1 in the procoagulant response of single, co
llagen-adherent platelets. Thromb Haemost 81:782-792.
5. Dekkers, D.W., P. Comfurius, W.M. Vuist, J.T. Billheimer, I. Dicker, H.J. Wei
ss, R.F. Zwaal, and E.M. Bevers. 1998. Impaired Ca2+-induced tyrosine phosphoryl
ation and defective lipid scrambling in erythrocytes from a patient with Scott s
yndrome: a study using an inhibitor for scramblase that mimics the defect in Sco
tt syndrome. Blood 91:2133-2138.
6. Vuist, W.M., M.A. Feijge, and J.W. Heemskerk. 1997. Kinetics of store-operate
d Ca2+ influx evoked by endomembrane Ca2+-ATPase inhibitors in human platelets.
Prostaglandins Leukot Essent Fatty Acids 57:447-450.
7. Heemskerk, J.W., W.M. Vuist, M.A. Feijge, C.P. Reutelingsperger, and T. Lindh
out. 1997. Collagen but not fibrinogen surfaces induce bleb formation, exposure
of phosphatidylserine, and procoagulant activity of adherent platelets: evidence
for regulation by protein tyrosine kinase-dependent Ca2+ responses. Blood 90:26
15-2625.
8. Vuist, W.M., I.N. Van Schaik, M. Van Lint, and A. Brand. 1997. The growth arr
esting effect of human immunoglobulin for intravenous use is mediated by antibod
ies recognizing membrane glycolipids. J Clin Immunol 17:301-310.
9. Brand, A., W.M. Vuist, I.N. Van Schaik, and M. Vermeulen. 1996. In vitro inve
stigation of immunoglobulin treatment mechanisms in autoimmune diseases. Clin Ex
p Rheumatol 14 Suppl 15:S27-30.
10. Vuist, W.M., R. Levy, and D.G. Maloney. 1994. Lymphoma regression induced by
monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig
signal transduction and is not prevented by tumor expression of high levels of
bcl-2 protein. Blood 83:899-906.
11. Vuist, W.M., M.J. Visseren, M. Otsen, K. Bos, F.A. Vyth-Dreese, C.G. Figdor,
C.J. Melief, and A. Hekman. 1993. Enhancement of the antibody-dependent cellula
r cytotoxicity of human peripheral blood lymphocytes with interleukin-2 and inte
rferon alpha. Cancer Immunol Immunother 36:163-170.
12. Hekman, A., A. Honselaar, W.M. Vuist, J.J. Sein, S. Rodenhuis, W.W. ten Bokk
el Huinink, R. Somers, P. Rumke, and C.J. Melief. 1991. Initial experience with
treatment of human B cell lymphoma with anti-CD19 monoclonal antibody. Cancer Im
munol Immunother 32:364-372.
13. Vuist, W.M., F. van Buitenen, A. Hekman, and C.J. Melief. 1990. Two distinct
mechanisms of antitumor activity mediated by the combination of interleukin 2 a
nd monoclonal antibodies. Cancer Res 50:5767-5772.
14. Vuist, W.M., F. v Buitenen, M.A. de Rie, A. Hekman, P. Rumke, and C.J. Melie
f. 1989. Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-p
an B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model. Can
cer Res 49:3783-3788.
15. Dullens, H.F., W. Vuist, M. Van der Maas, and W. Den Otter. 1986. The role o
f host lymphocytes and host macrophages in antitumor reactions after injection o
f sensitized lymphocytes and tumor target cells into naive mice. Cancer Immunol
Immunother 23:113-118.
16. Dullens, H.F., S. Schakenraad, A. Oostdijk, W. Vuist, M. Van der Maas, and W
. Den Otter. 1986. Specific tumoricidal activity of cytotoxic macrophages and cy
totoxic lymphocytes. Cancer Immunol Immunother 22:100-106.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
TRAINING
Mid-America Course in Toxicology, Kansas City, KS, 2008
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
PROFESSIONAL AFFILIATIONS
American Association of Immunologists
American Association for the Advancement of Science
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
HONORS & AWARDS
The American Association of Cancer Research Travel Grant, 1994
Netherlands Cancer Society Fellowship (two years), 1991
Fellow, Dutch Cancer Society, Year